Patient, health care and pharmaceutical promotion – a critical inventory Hans-Joachim Both Neurologist, member of IPPNW group Berlin mail adress :

Slides:



Advertisements
Similar presentations
6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Advertisements

Understanding and Responding to Pharmaceutical Promotion
Competing interests Jaideep A Gogtay MD Conflict of Interest Employee of Cipla Ltd.
Shana Schwarz.  Type I (i.e. false positive) ◦ Occurs by rejecting the null hypothesis even when it is true. ◦ In other words, this is the error of accepting.
Canadian Nurse Practitioners and Pharmaceutical Influences
CPME Comité Permanent des Médecins Européens Standing Committee of European Doctors Doctors and industry - European perspective International.
Do Health Care Regulation and Physician-Industry Interaction Influence Antibiotic Resistance Rates? The Example of Antimicrobial Prescribing and Dispensing.
Pharmaceutical Sales representatives July 2014 Tim Reed Health Action International This document arises from HAI Europe’s Operating Grant 2014, which.
International Seminar on Drug Advertising Canadian Experience Brazilian Health Surveillance Agency and Pan American Health Organization Brasilia, Brazil.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
ABCWINRisk and Statistics1 Risk and Statistics Risk Assessment in Clinical Decision Making Ulrich Mansmann Medical Statistics Branch University of Heidelberg.
May 13, 2005 North Carolina State University Off-Label Use and Product Liability: Basic Principles David L. Baumer, Ph.D., J.D., Attorney at Law, Professor.
Understanding decision making - Investigating complaints Tony Kofkin Director of Investigations Health Care Complaints Commission Dr Walid Jammal Medical.
The Cost Effectiveness of Direct to Consumer Advertising for Prescription Drugs Adam Atherly and Paul H. Rubin Emory University.
Personal and Consumer Health 1. Objectives 1.Demonstrate the ability to access and describe health information, health products, and health services in.
Who stands behind the word? A journal editor’s view of ghostwriting Gavin Yamey MD Deputy editor, wjm Assistant editor, BMJ.
External Influences on Prescribing Practice Karen Ford.
Equipoise and the ethics of clinical research l When is it ethical to initiate a randomized- controlled trial? Freedman, NEJM, l “There exists (or.
Direct-to-Consumer Advertising of Prescription Drugs: Looking Back, Looking Forward Kathryn J. Aikin, Ph.D. Division of Drug Marketing, Advertising and.
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
 Pharmacovigilance – Patient’s standpoint Steve Arlington May 2007.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
Introduction To Pharmacy Practice
Drug Companies and the Media by Dr. Angus Robin & Dr. Nabeela Hasan Bradford VTS 2008.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
Impact Health NDAC Meeting Stewart Levy R.Ph. January 14, 2005.
INTRODUCTION TO RA.
“Delivering Therapeutic Agents” - Marketing and Communication Strategies of Drug Companies Safura Nantogmah.
Medicines Transparency Alliance14/10/ Medicines promotion: innovative tools to promote rational use Carole Piriou Project officer Rational use of.
+ Conflict of Interest in Physician-Industry Relationships.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
Disclosure of Financial Conflicts of Interest in Continuing Medical Education Michael D. Jibson, MD, PhD and Jennifer Seibert, MD University of Michigan.
Program Co-Development in CME: Where have we been? Where are we going? Workshop Facilitators: Dr. Craig Campbell Dr. Jamie Meuser September 21,
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
+ Role of Industry in Clinical Care, Research, and Education.
Understanding and responding to pharmaceutical promotion: A practical guide  Americas  Europe  Western Pacific  Eastern Mediterranean  Africa  South-East.
The Physician - Pharma Relationship.  Is very old and very close  But are the goals of pharmaceutical companies and medicine the same?
$100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 Terms Clinical Trial Facts.
Inside Clinical Trials ® ALL RIGHTS RESERVED. What is a clinical trial? ALL RIGHTS RESERVED.
Comments to „A“: „The health care system“ Arie Hasman & Achim Hochlehnert Health Care in the Information Society - on the Prognosis for the Year 2013 Workshop.
BDH Discovering Tomorrow’s Healthcare Solutions Today Clinical Research Services, Inc. Basil Halliday, M.Sc. President & CEO BDH Clinical Research Services.
Ethics Case 1 Remonte. Rivera, K., Sagayaga. Siy. Talan.
European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
Government Regulatory Agencies and Impact on Consumer Choices Presentation.
Off Label Use in Managed Care Pharmacy Presentation Developed for the Academy of Managed Care Pharmacy Updated February 2015.
Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.
An Orientation To Community Benefit: What Hospital Staff Need To Know.
Off-Label Use in Managed Care Pharmacy Presentation Developed for the Academy of Managed Care Pharmacy Updated: February 2016.
RAC Regulatory Affairs Certification
CLINICAL TRIALS.
Off-label Use.
A capacity building programme for patient representatives
Disclosure UK Talking about Transparency.
Direct to Consumer Advertising in Prescription Medicine
Cooperation for Better Regulation
Introduction to Clinical Pharmacy
Disclosure UK Talking about Transparency.
Value of Pharmaceuticals in Managed Care Pharmacy
Critical Reading of Clinical Study Results
Value of Pharmaceuticals in Managed Care Pharmacy
Value of Pharmaceuticals in Managed Care Pharmacy
Medicine Safety.
AGREEMENT FOR TRANSPARENCY The Case of Mexico
Pharmaceutical Industry & Consumers
Prescription of New Drugs by General Practitioners in Pakistan: An Exploration into Information Sources, Prescription Influences and General Attitudes.
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
US Consumer Perceptions of Pharmaceutical Companies
Value of Pharmaceuticals in Managed Care Pharmacy
Presentation transcript:

Patient, health care and pharmaceutical promotion – a critical inventory Hans-Joachim Both Neurologist, member of IPPNW group Berlin mail adress : Declaration of my conflicts of interest : none Workshop „Promotion of pharmaceutical industry and ist Influence on public health“ IPPNW World Congress, Basel 2010 Basel, Dr. J. Both Workshop Promotion of Pharm.Ind. and its Influence on Public Health1

“Modern” Types of Marketing Pharmaceutical sales representatives (PSR) & samples, gifts, sponsered continuing education Key physician „opinion leaders“ Publication bias in journals, conflicts of interest Ghost-writing of journal articles Funding of patient groups, medical societies and even guidelines Observational non-interventional studies 2 Dr. J. Both Workshop Promotion of Pharm.Ind. and its Influence on Public Health IPPNW/Basel,

New Medicines Basel, Dr. J. Both Workshop Promotion of Pharm.Ind. and its Influence on Public Health 3 Are not necessarely better than existing treatment Tested on highly selected groups, most not on old and comorbid patients Over a short period, thus, rarely harmful effects not yet to be seen To be approved for marketing often compared with placebo, no need of advantage over existing therapies

Basel, Dr. J. Both Workshop Promotion of Pharm.Ind. and its Influence on Public Health 4 La révue préscrire, 2005, Innovation en panne et prise de risques New medicines and indications in France

Pharmaceutical Sales Representatives [PSR] An estimated PSR pay 20 million visits to hospitals and private doctors every year amounting to estimated costs of approx. 2,5 billion €/year in Germany. Consequently, for these and other reasons, marketing expenses are about double of those spent for research and development (Lieb, D. Ärztebl. 2010) PSR distribute drug samples and information brochures, invite to educational events promoting off-label-use and participation in observational non-interventional studies Basel, Dr. J. Both Workshop PromotioPharm.Ind. and its Influence on Public n of Health 5

Value of information brochures About 94% of doctors information brochures edited by pharmaceutical industry lacks valid scientific verification Relevant negative aspects are discarded whereas positive aspects are exaggerated References to published literature are mostly missing, resp. wrong or misquotations The brochures no longer indicate the price of the medicinal product Basel, Dr. J. Both Workshop Promotion of Pharm.Ind. and its Influence on Public Health6

Basel, Dr. J. Both Workshop Promotion of Pharm.Ind. and its Influence on Public Health 7 Steinman, MA et al., 2006, Annals of Intern. Medicine Gabapentin (Neurontin) use for unapproved indications = off-label-use

Is Prescribing Influenced ? 84% of all medical doctors [MDs] believe that they are almost refractory to respective attempts. These MDs believe that the probability of their colleagues being influenced is 3-4 times higher as compared to themselves. A study showes that MDs causing high prescription costs are more likely to be in contact with PSR and / or sponsored educational events than those with low prescription costs (Lieb et al. Dt. Ärzteblatt 2010) Basel, Dr. J. Both Workshop Promotion of Pharm.Ind. and its Influence on Public Health8

Basel, Dr. J. Both Workshop Promotion of Pharm.Ind. and its Influence on Public Health 9 Survey of hospital doctors about sales representatives‘ influence Steinman MA et al., 2001, American Journal of Medicine

Observational Non-interventional Studies Were conceived for getting information about risks and efficacy of a particular drug if applied to a wide variety of patients In fact, respective results are not used for increasing drug safety and/or efficacy but rather are discarded Most of such „studies“ are perverted to a pure marketing instrument Result in a win-win situation for MDs/industry Basel, Dr. J. Both Workshop Promotion of Pharm.Ind. and its Influence on Public Health 10

Educational training + Journals So-called peer group leaders are paid for giving talks about new medicinal products Publications are written by so-called „ghost- writers“ and talks for medical training by marketing agencies Well known specialists/professors only give their names – another win-win situation ! Basel, Dr. J. Both Workshop Promotion of Pharm.Ind. and its Influence on Public Health 11

National guidelines Professional associations are responsible for establishing their specific treatment and “best practice” guidelines Therapeutic treatment schemes should be: - established on highest scientific standard - evidence based, unbiased etc. But in fact, often up to 100% of the members of commissions responsible for national guidelines have conflicts of interest! Basel, Dr. J. Both Workshop Promotion of Pharm.Ind. and its Influence on Public Health 12

Publication Bias With respect to a marketing authorisation, FDA and EMA mandate the submission of all studies performed with a new drug But in medical journals studies are frequently manipulated: positive results for test drugs are exaggerated, whereas negative results are discarded or attenuated Therefore, benefits and risks of a new drug described in publications can differ substantially from those in the FDA/EMA data Basel, Dr. J. Both Workshop Promotion of Pharm.Ind. and its Influence on Public Health 13

Patient organizations For about 10 years, pharmaceutical marketing is directly and substantially influencing the consumers/patients High costs of medicines for special diseases are directly associated with strong sponsoring of such patient groups The respective Commission (Brussels) is under increasing pressure regarding an opening of the market for prescription medicines and for “Direct To Consumer Advertising (DTCA)” Basel, Dr. J. Both Workshop Promotion of Pharm.Ind. and its Influence on Public Health 14

Advertisement for Vioxx Basel, Dr. J. Both Workshop Promotion of Pharm.Ind. and its Influence on Public Health15 From: Dorothy Hamill Olympic gold medal in 1976 Ask your doctor or other healthcare professional

Medical doctors taken in tow by industry More than 90% of doctors in private practice get their knowledge about medicinal products through a closed network: Like in a vicious circle, pharmaceutical companies pay on different levels for all needs of a medical doctor - from samples, gifts regarding social and educational events up to an increasing number of publications in medical journals is tainted with conflicts of interests. → Hardly any chance to escape ! Basel, Dr. J. Both Workshop Promotion of Pharm.Ind. and its Influence on Public Health16